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the gastrointestinal tract is home to over 10
14 bacteria that 
collectively form the intestinal microbiome, and their joint 
genetic repertoire is larger than the human genome.1 These 
symbiotic bacteria establish and maintain the gut immune 
system, and contribute to the breakdown of complex non-
digestible plant-derived polysaccharides.2,3 The relatively 
recent technological advances in genomics have revolutionized 
the study of the intestinal microbiome. It is now possible to 
sequence mixed microbial genetic material directly extracted 
from environmental samples without prior laboratory culture of 
individual species. This emerging field, known as metagenomics, 
enables a survey of the different microorganisms present in a 
specific environment.4 Several large-scale projects such as the 
Human Microbiome Initiative have characterized microbial 
genomes from hundreds of isolated human symbionts and have 
shed light on the complex interplay between the human host 
and its microbial populace, and how this changes in health and 
disease. 
This article aims to discuss the emerging body of knowledge 
that links the gut microbiome to the development of obesity and 
metabolic disease. The growing prevalence of overweight and 
obesity are easily linked to the sedentary lifestyles and calorie-
dense diets typical of ‘Westernized’ countries. There is, however, 
growing evidence that there are  powerful physiological 
processes that restrict any  cognitive 
mechanisms to reduce excessive weight by 
drastic changes in lifestyle. The reason is 
that those same physiological processes 
maintain body weight within a narrow 
range.5 In this respect, obesity is 
increasingly recognized as a 
disease rather than as a willful 
choice. 
the obesity MicrobioMe
The involvement of 
the gut microbiome in 
obesity came to light from 
studies that compared 
the microbiota between 
lean and obese mice 
and human subjects. 
Using obese, leptin-
deficient ob/ob mice, 
Ley et al showed a difference in the ratio of the two dominant 
intestinal phyla – Bacteroides and Firmicutes, between obese 
mice and their lean counterparts.6 The reason for using 
leptin-deficient mice is that they exhibit relatively mild 
hyperglycemia and obesity. This seminal paper showed that 
in mice, kinship is a strong determinant of caecal microbial 
composition. Furthermore, Ley et al showed that regardless of 
family membership, obesity is associated with a 50% reduction 
of Bacteroides species and a greater proportion of Firmicutes 
relative to lean mice. These findings were reproduced by Ley 
et al in humans7 and subsequently by other investigators.8-10 
Other investigators have however failed to fully reproduce 
these findings,11 possibly due to methodological differences in 
determining the composition of the microbiome. 
 Further insight into the role of the microbiome in 
obesity comes from germ-free (GF) mice. GF mice are born 
and bred under special conditions to control their exposure to 
microbes, and can be inoculated by specific bacterial strains for 
research purposes (gnotobiotics). Studies have shown that GF 
mice are leaner and resistant to obesity when consuming a high 
fat, high carbohydrate diet.12 Subsequently, Backhead 
et al showed that the transfer of caecal bacteria 
harvested from normal mice to their GF 
counterparts is accompanied by a 60% increase 
in body fat content and insulin resistance, 
despite a reduced fat intake.13 Turnbaugh et 
al proposed that the gut microbiota of obese 
individuals are more efficient at extracting 
calories from the diet when compared to 
microbes from lean individuals. In a series 
of elegant experiments, they transferred 
caecal microbes from obese and lean 
mice to GF mice, the investigators 
showed that wild-type GF mice exhibit 
a greater increase in body fat when 
colonized by bacteria from obese 
donors than GF mice colonized by 
caecal bacteria from lean donors.14 
Similar findings have been 
reported in human studies, where 
a randomized controlled trial 
reported significantly improved 
insulin sensitivity in male patients 
with metabolic syndrome who 
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received allogenic fecal bacteria from a lean donor compared 
to those who received an autologous gut microbiota infusion.15 
This study also identified a significant increase in intestinal 
butyrate-producing bacteria in recipients of microbiota from a 
lean donor.  Comparable results have been reported in two large 
metagenome-wide association studies.16-17 Karlson et al showed 
that T2DM is accompanied by a decrease in butyrate-producing 
Roseburia and Faecalibacterium prauznitzii when compared to 
healthy subjects.16 
the effects of MicrobioMe-DeriVeD ProDucts 
Butyrate, along with propionate and acetate, are short-chain 
fatty acids (SCFAs) derived from the bacterial degradation 
of complex polysaccharides in the gut.18 They have important 
metabolic roles, with butyrate acting as a metabolic substrate for 
colonic epithelial cells. Studies have implicated these SCFAs in 
the pathogenesis of inflammatory bowel disease (IBD). Vernia 
et al identified low fecal concentrations of butyrate in ulcerative 
colitis,19 and butyrate enemas suppress inflammation in distal 
ulcerative colitis.20 Other studies have investigated the systemic 
anti-inflammatory effect of butyrate in IBD,21-22 while Gao et 
al report that oral butyrate administration improves insulin 
sensitivity and energy expenditure in obese mice.23 
Butyrate is a histone deacetylase (HDAC) inhibitor. 
Lysine residues in histone proteins undergo post-translational 
modification as part of the epigenetic regulation of gene 
expression. The acetylation of lysine residues in histone proteins 
leads to nucleosome unfolding and transcriptional activation. 
Conversely, histone deacetylase removes acetyl groups on lysine 
in histone proteins, leading to transcriptional repression.24 Gao 
et al showed that butyrate administration is associated with 
increased expression of PGC-1α, which leads to increased fatty 
acid oxidation, mitochondrial activity and energy expenditure.23 
This directly links microbiome-derived SCFA to changes in host 
gene expression pathways that promote insulin sensitivity. 
SCFA also act on host signaling pathways by binding to 
G-protein coupled receptors in enteroendocrine cells. Butyrate 
has been shown to trigger production and release of the 
peptide hormone PYY from intestinal enterocytes.25 Butyrate 
is also postulated to play a role in the maintenance of intestinal 
epithelial integrity, thereby preventing the translocation of 
endotoxins produced by intestinal Gram-negative bacteria. 
Obesity and insulin resistance are associated with a chronic 
subclinical inflammatory response,26 and studies have shown 
that high fat diets in mice increase the proportion of endotoxin-
producing gut microbes and lead to insulin resistance.27 
The gut microbiome is intimately linked to the regulation 
of carbohydrate and lipid metabolism in the host. Specifically, 
research has shown that butyrate-producing bacteria improve 
insulin sensitivity in both animal and human subjects,23,28 T2DM 
and obesity are also linked to changes in the composition of the 
microbiome, although evidence regarding the causality of these 
changes is not clear, for the observed changes in the microbiome 
might be secondary to the altered intestinal motility and bacterial 
overgrowth seen in T2DM. Critically, clinical trials involving 
SCFA supplementation and microbial transfer are needed in 
order to evaluate any therapeutic application from this emerging 
field of research. 
 
the effect of host factors on the gut MicrobioMe
The widespread availability of antibiotics has resulted in a 
number of public health benefits and a reduced infectious disease 
burden. However, a growing body of evidence links antibiotic use 
to the obesity pandemic.29 Thuny et al link long term (6 week) 
vancomycin use in infective endocarditis to weight gain in adult 
males.30 Short term administration of oral ciprofloxacin has been 
linked to rapid and permanent changes in the composition and 
diversity of the gut microbiome.31 In a cohort of over 28,000 
Danish subjects, born from normal weight women, an early 
exposure to antibiotics before the sixth month of age has been 
linked to an increased risk of being obese later on in life.32 These 
findings reinforce the need for more judicious use of antibiotics, 
and further emphasize the functional interaction between the gut 
microbiome and host metabolism. 
 Host diet is also an important determinant of 
microbiome composition. Changes in fecal enterotypes, as 
determined by Prevotella and Bacteroides, have been shown to 
occur in response to long term protein-rich vs carbohydrate-rich 
diets in man.33 
conclusion
The gut microbiome has an intimate relationship with the 
host organism that is vital for energy homeostasis. Studies 
suggest that changes in microbial composition can lead to obesity 
through various mechanisms. Although this area of research is 
still in its infancy, it opens up a number of potential therapeutic 
approaches to facilitate weight loss or treat obesity and its 
complications. 
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